A big, important step in (public) health (economics)

The NY Times reports that four large health insurers have agreed to release claims data to academics on a regular basis. Claims data will allow us (researchers) to look in much greater detail at what is driving excess costs but much more importantly, to find out how quickly physicians are taking up new (and hopefully better) … Continue reading A big, important step in (public) health (economics)

Wapner on Avastin

Always interesting and engaging, Jessica Wapner has discussed the bevacizumab (Avastin) saga and a recent recommendation made to the FDA that the drug is not appropriate for the treatment of breast cancer. It is a difficult example because the drug is prohibitively expensive, will evoke a positive response in a relatively small proportion of patients, … Continue reading Wapner on Avastin